Why the study?
Although CXCR-2 regulates monocyte mobilization in hypertension and cardiac remodeling, its role in the development of hypertensive AF was unknown.
Does CXCR-2 inhibition prevent atrial remodeling and AF inducibility in a hypertensive mouse model?
Does CXCR-2 inhibition prevent atrial remodeling and AF inducibility in a hypertensive mouse model?
CXCR-2 drives monocyte infiltration and atrial remodeling in hypertension, suggesting CXCR-2 blockade as a potential therapeutic strategy for atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support CXCR-2 as target in hypertensive AF models; leaves open human translation and trials.
Atrial fibrillation (AF) is frequently associated with increased inflammatory response characterized by infiltration of monocytes/macrophages. The chemokine receptor CXCR-2 is a critical regulator of monocyte mobilization in hypertension and cardiac remodeling, but it is not known whether CXCR-2 is involved in the development of hypertensive AF. AF was induced by infusion of Ang II (angiotensin II; 2000 ng/kg per minute) for 3 weeks in male C57BL/6 wild-type mice, CXCR-2 knockout mice, bone marrow-reconstituted chimeric mice, and mice treated with the CXCR-2 inhibitor SB225002. Microarray analysis revealed that 4 chemokine ligands of CXCR-2 were significantly upregulated in the atria during 3 weeks of Ang II infusion. CXCR-2 expression and the number of CXCR2 + immune cells markedly increased in Ang II–infused atria in a time-dependent manner. Moreover, Ang II–infused wild-type mice had increased blood pressure, AF inducibility, atrial diameter, fibrosis, infiltration of macrophages, and superoxide production compared with saline-treated wild-type mice, whereas these effects were significantly attenuated in CXCR-2 knockout mice and wild-type mice transplanted with CXCR-2-deficient bone marrow cells or treated with SB225002. Moreover, circulating blood CXCL-1 levels and CXCR2 + monocyte counts were higher and associated with AF in human patients (n=31) compared with sinus rhythm controls (n=31). In summary, this study identified a novel role for CXCR-2 in driving monocyte infiltration of the atria, which accelerates atrial remodeling and AF after hypertension. Blocking CXCR-2 activation may serve as a new therapeutic strategy for AF.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: